GREENWOOD VILLAGE, Colo., July 12, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), a biopharmaceutical company conducting clinical trials on its three lead drugs (Ampion™, Optina™ & Zertane™), licensing distribution of these drugs and developing additional new drugs, today announced the pricing of its previously announced underwritten public offering of 4,615,400 shares of its common stock, offered at a price to the public of $3.25 per share. The gross proceeds to Ampio from this offering are expected to be $15.0 million, before deducting the underwriting discount and other estimated offering expenses payable by Ampio. Ampio and certain of its stockholders have granted the underwriters a 45-day option to purchase at the public offering price up to an aggregate of 692,310 additional shares of common stock to cover overallotments, if any. The offering is expected to close on or about July 18, 2012, subject to customary closing conditions.
Aegis Capital Corp. and Fordham Financial Management, Inc. are acting as joint book-running managers for the offering.The offering is being made pursuant to a shelf registration statement that Ampio filed with the Securities and Exchange Commission ("SEC") and is effective. A preliminary prospectus supplement and accompanying base prospectus relating to the offering were filed with the SEC and a final prospectus supplement and accompanying base prospectus will be filed with the SEC. When available, copies of the final prospectus supplement and accompanying base prospectus relating to the offering may be obtained by contacting Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY, 10019, telephone: 212-813-1010 or email: email@example.com or Fordham Financial Management, Inc., 17 Battery Place, South, Suite 643, New York, New York 10004. Electronic copies of the final prospectus supplement and accompanying base prospectus will also be available on the website of the SEC at http://www.sec.gov. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV